Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Measuring the binding of SARS-CoV-2 antibodies to the COVID spike protein using SPR

Ryan Denomme, the CEO of Nicoya, speaks to News-Medical on their SARS-CoV-2 research using their SPR technology.

From Nicoya Lifesciences 28 May 2020

A new therapeutic approach to improve the health of diabetic patients

Scientists at Sanford Burnham Prebys Medical Discovery Institute have mapped for the first time the vast network of proteins that interact with proinsulin, the protein the body normally processes into insulin.

27 May 2020

Phase IIB clinical trial initiated for treating hepatitis B-associated liver cancer

The first patients have been dosed in a multi-regional Phase IIB randomized, placebo-controlled clinical trial for the treatment of hepatitis B-associated liver cancer.

19 May 2020

X-ray experiments demonstrate a new way to block the entry of SARS-CoV-2

As scientists across the globe race to develop a vaccine against SARS-CoV-2, the coronavirus that causes COVID-19, an international team led by Davide Corti at Vir Biotechnology and David Veesler at the University of Washington has been working around the clock on a complementary approach - identifying neutralizing antibodies that could be used as a preventative treatment or as a post-exposure therapy.

19 May 2020

CELLINK announces partnership with AstraZeneca to provide advanced 3D-bioprinted liver organoids

CELLINK, focused on the development and commercialization of innovative bioprinting technologies and bioinks, announced today that the company will collaborate with AstraZeneca to provide advanced 3D-bioprinted liver organoids for drug discovery purposes in cardiovascular, renal and metabolic diseases.

From CELLINK 15 May 2020

Study provides new insights on mechanisms that promote cancer

Like subway com muters on a crowded train, cells generally prefer not to be packed in too tightly. In fact, they have set up mechanisms to avoid this, a phenomenon called "contact inhibition." A hallmark of cancer cells is that they lack this contact inhibition, and instead become pushy, facilitating their spread.

14 May 2020

Study explores whether senicapoc drug can mitigate lung damage in COVID-19 patients

Scientists around the globe are working to identify approved and investigational drugs that can be repurposed to treat COVID-19.

13 May 2020

Optibrium’s StarDrop now powered by OpenEye Scientific’s cheminformatics toolkits

Optibrium and OpenEye Scientific, leading providers of software and services for drug discovery, today announced that StarDrop, Optibrium’s software for small molecule design, optimization and data analysis, is now powered by OpenEye Scientific’s cheminformatics toolkits.

From Optibrium Ltd. 13 May 2020

Sanford director receives major grant to advance broad-spectrum antivirals for respiratory diseases

Sanford Burnham Prebys Medical Discovery Institute is pleased to announce that Sumit Chanda, Ph.D., has received a $10.2 million, four-year grant from the Department of Defense to develop and advance broad-spectrum antivirals for respiratory diseases.

12 May 2020

Regeneron and CCPM collaborate to advance human genetics, precision medicine

Regeneron Pharmaceuticals, Inc. and the Colorado Center for Personalized Medicine at the University of Colorado Anschutz Medical Campus today announced a large-scale research collaboration designed to advance the field of human genetics and precision medicine through the sharing of 450,000 DNA samples and corresponding health records from de-identified, consented patient participants in the expansive UCHealth system.

11 May 2020

GCS centers support research to fight against global COVID-19 pandemic

In December 2019, the world learned of a new and deadly pathogen. News coming out of Wuhan, China confirmed public health experts' worst fears--a novel coronavirus appeared to have jumped from animals to humans.

11 May 2020

AI VIVO seeks pharma, biotech collaboration partners to advance drug candidates for COVID-19

AI VIVO has announced that it is seeking pharma and biotech collaboration partners to progress therapeutic candidates for COVID-19.

11 May 2020

New breakthrough in chemistry could accelerate drug development

Scientists have successfully developed a new technique to reliably grow crystals of organic soluble molecules from nanoscale droplets, unlocking the potential of accelerated new drug development.

8 May 2020

A comprehensive review on therapeutic properties of plants

Nature is an amazing source for food, shelter, clothing and medicine. An impressive number of modern drugs are isolated from many sources such as plants, animals and microbes.

8 May 2020

Study investigates potential use of metal catalysts to create drug discovery platform

The use of metals in drug delivery could offer major benefits, including allowing for lower dosages of a medication to achieve therapeutic effects.

6 May 2020

Quantum machine learning may lead to possible treatments for COVID-19

Quantum machine learning, an emerging field that combines machine learning and quantum physics, is the focus of research to discover possible treatments for COVID-19, according to Penn State researchers led by Swaroop Ghosh, the Joseph R. and Janice M. Monkowski Career Development Assistant Professor of Electrical Engineering and Computer Science and Engineering.

5 May 2020

Scripps professor receives Research Program Award for advancing RNA-targeting medicines

In recognition of his high-impact work advancing the field of RNA-targeting medicines, the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, has awarded Scripps Research Chemistry Professor Matthew Disney, PhD, a prestigious Research Program Award, to aid Disney's development of treatments for incurable diseases such as Alzheimer's, Parkinson's, ALS and frontotemporal dementia.

4 May 2020

Astellas and Insilico collaborate on new AI technology to develop new drug candidates

Insilico Medicine has announced that it has entered into a research collaboration agreement with Astellas Pharma Inc. to utilize Insilico Medicine's novel generative artificial intelligence technology aimed at accelerating development of candidates against a conventionally challenging target family.

28 Apr 2020

Researchers harness the power of AI to accelerate drug discovery

As the COVID-19 crisis continues to develop, researchers around the world are attempting to find the most effective treatment to combat the poorly understood virus behind this disease.

27 Apr 2020

Investigational drug may hold benefit for patients with lung and ovarian cancers

In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers from The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division and Ipsen Biopharmaceuticals reported the preclinical discovery and early-stage clinical development of this novel drug. IPN60090, now under investigation in a Phase I trial, may hold benefit for certain patients with lung and ovarian cancers.

27 Apr 2020

Drug Discovery News and Research

Further Reading

Measuring the binding of SARS-CoV-2 antibodies to the COVID spike protein using SPR

A new therapeutic approach to improve the health of diabetic patients

Phase IIB clinical trial initiated for treating hepatitis B-associated liver cancer

X-ray experiments demonstrate a new way to block the entry of SARS-CoV-2

CELLINK announces partnership with AstraZeneca to provide advanced 3D-bioprinted liver organoids

Study provides new insights on mechanisms that promote cancer

Study explores whether senicapoc drug can mitigate lung damage in COVID-19 patients

Optibrium’s StarDrop now powered by OpenEye Scientific’s cheminformatics toolkits

Sanford director receives major grant to advance broad-spectrum antivirals for respiratory diseases

Regeneron and CCPM collaborate to advance human genetics, precision medicine

GCS centers support research to fight against global COVID-19 pandemic

AI VIVO seeks pharma, biotech collaboration partners to advance drug candidates for COVID-19

New breakthrough in chemistry could accelerate drug development

A comprehensive review on therapeutic properties of plants

Study investigates potential use of metal catalysts to create drug discovery platform

Quantum machine learning may lead to possible treatments for COVID-19

Scripps professor receives Research Program Award for advancing RNA-targeting medicines

Astellas and Insilico collaborate on new AI technology to develop new drug candidates

Researchers harness the power of AI to accelerate drug discovery

Investigational drug may hold benefit for patients with lung and ovarian cancers

eBook: Using iPSCs models for human disease research and drug discovery eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News